Medical network - on September 14, recently, in the Chinese medical association (CDS) complications education management conference, 2017 CDS diabetes education and the management group medtronic, hand in hand together release insulin pump therapy nursing management standard of the People's Republic of China (hereinafter referred to as the "specification"), and start the first Chinese in the country to "pump" training certification program to insulin, driving China's diabetes insulin pump therapy to "pump" as the center, collaborative patients, hospitals and manufacturers of new management mode, enhancing the management level of domestic insulin pump.
Editor in chief of "specification", the Chinese medical association of diabetes complications the education and management group leader xiao-hui guo said: "the" specification "for the first time put forward the insulin" pump division "concept, and to the operation of the hospital insulin pump therapy management made more specific guidance, to strengthen the hospital medical cooperation, promote optimization in patients with slow disease management is of great significance."
Industry insiders pointed out that the operator is a key link in the promotion and use of insulin, and strengthening the training and reserve of special talents in the hospital is conducive to the sinking and market expansion of products.
Professional "pump master" bridge
The reporter understands that with the increasing demand of diabetes treatment in China, the use of insulin pump has increased greatly. 2009 insulin pump treatment guidelines of China officially released and pointed out that the use of insulin pump has more than 20 years of history, in the world of DCCT results released laid the intensie insulin therapy in the important position of diabetes control and complications, and also for the clinical application of insulin pump to provide the high quality clinical evidence.
Has the expert introduction, at present our country has 3000 hospitals to carry out the insulin pump treatment, short-term insulin pump therapy in patients with more than million each year, the individual has more than 50000 in patients undergoing long-term insulin pump therapy. However, compared with the international level, China's penetration rate is not high and the market needs further development.
It is reported that there are not many brands of insulin pumps in the Chinese market. The imported first-line brands include medtronic and danner, and the second-tier brands include roche, delt, kai and tup. The domestic brands are mainly foia, phoenix, maishitong, rayyu and vertex etc. Industry insiders point out that after 2010, domestic brands gradually enter the domestic market, but face many difficulties, such as technical bottleneck, professional staff reserve and brand awareness. Among them, professional staff reserves are considered to be the most easily improved priority in the short term.
In fact, not only do doctors play the role of decision makers in the treatment of insulin pumps in the hospital, more and more nurses are now taking on the installation, nursing and maintenance of insulin pumps. Due to domestic insulin pump treatment in the hospital there is biggish difference between management specification, health care workers in practice still exist the phenomenon of insufficient standard, at the same time, the management of hospital on insulin pump needs further systematic, between departments and coordination between the medical power, as well as guide and follow-up of patients, can further improve the clinical effect of insulin pump therapy and quality.
For this case, the "specification" in insulin pump treatment guidelines of the People's Republic of China on the basis of the construction of hospital insulin pump treatment team to make a clear plan, and use at home and abroad and referring to the experience, the operation and management of common problems, the insulin pump treatment team daily work matters, personnel training and so on to make detailed guidance.
For the first time, the specification puts forward the concept of insulin pump. By integrating the endocrine specialized subject knowledge, as well as the diabetes education, insulin pump quality control management, staff training and skills, will be in "pump" wear pump patients, doctors and bridge between insulin pump manufacturers.
"The pump division has three main core functions: first, give the patient professional evaluation, guidance, education and follow-up, and strengthen the self-management awareness of the pump patients," guo said. Second, provide professional training for the nurses' team and optimize the nursing work in the hospital. Third, make insulin pump manufacturer to obtain timely quality control technical support.
, medtronic diabetes business group vice President of greater China Chen said: "the specification release and training certification program, to foster a batch of domestic insulin pump management professionals, and help more patients get standardized nursing, and self management knowledge and ideas." Reporters have learned that the first batch of the regulations and training certification programs will be rolled out in 11 cities. The first certification training program is expected to produce nearly 500 insulin pumps.
The co-payment mechanism reduces the burden of patients
At this seminar, the reporter also learned that the promotion of insulin pump in China was also limited by price. At present, the market for insulin pumps is expensive, costing hundreds of dollars per set (the smart insulin pumps cost thousands of dollars each). In developing countries such as China, India and Brazil, many of these patients are low-income, so inexpensive insulin injections are more likely to be accepted.
In addition, in the United States, the European Union, Japan and other major developed countries and regions in the world's health care system, a complete coverage of type 1 diabetes insulin pump therapy have been implemented, some developing countries such as South Africa, Turkey also have health coverage. Therefore, experts also called on the government to further expand the scope of medical insurance and medical assistance to alleviate the heavy burden of treatment for people with diabetes, especially type 1 diabetes.
In 2015, according to medtronic on insulin pump therapy for the first time was incorporated into the local medical treatment scope - Qingdao social medicare apt (material) aid project, project rescue object is the Qingdao area under the age of 18 one full year of life, people with type 1 diabetes towns and rural medicare beneficiaries. Patient when buying medtronic supply of insulin pump only need to pay 30% of the insulin pump prices, the remaining 70% by a rescue fund to pay social security bureau, Qingdao to insulin pump required consumables will also take the same proportion pay jointly by the bail-out fund and patients.
|
